$CRVS
Corvus Pharmaceuticals, Inc. Stock $crvs

$crvs Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000155837022003281 Filed on March 10, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.022M	$2.056M	$2.184M
YoY Change	-24.83%	-36.35%	-24.95%
% of Gross Profit
Research & Development	$4.788M	$6.991M	$9.106M
YoY Change	-33.41%	5.62%	15.9%
% of Gross Profit
Depreciation & Amortization	$93.00K	$108.0K	$119.0K
YoY Change	-33.57%	-28.0%	-25.63%
% of Gross Profit
Operating Expenses	$6.810M	$9.047M	$11.29M
YoY Change	-31.07%	-8.11%	4.86%
Operating Profit		-$9.047M	-$11.29M
YoY Change		-8.11%	4.86%
Interest Expense	-$2.567M	-$1.720M	-$462.0K
YoY Change	1016.09%	-3540.0%	-388.75%
% of Operating Profit
Other Income/Expense, Net	$141.0K	$94.00K
YoY Change
Pretax Income	-$9.236M	-$10.67M	-$11.75M
YoY Change	-133.77%	8.95%	10.75%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.236M	-$10.67M	-$11.75M
YoY Change	-133.77%	8.95%	10.75%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.20	-$0.24	-$0.28
Diluted Earnings Per Share	-$0.20	-$0.24	-$0.28
COMMON SHARES
Basic Shares Outstanding	46.55M	42.42M	42.25M
Diluted Shares Outstanding		43.95M	42.25M

Balance Sheet

Concept	2021 Q4	2021 Q3	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$69.45M	$76.33M	$66.46M
YoY Change	56.77%	48.5%	12.07%
Cash & Equivalents	$63.46M	$72.30M	$58.92M
Short-Term Investments	$5.993M	$4.034M	$7.545M
Other Short-Term Assets	$128.0K	$98.00K	$80.00K
YoY Change	-68.47%	-78.13%	-80.63%
Inventory
Prepaid Expenses
Receivables	$507.0K	$276.0K
Other Receivables	$32.00K	$47.00K
Total Short-Term Assets	$71.31M	$78.76M	$69.12M
YoY Change	57.3%	49.99%	14.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$451.0K	$539.0K	$647.0K
YoY Change	-50.22%	-48.57%	-42.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$34.27M	$36.33M	$38.05M
YoY Change	-7.95%
Other Assets	$236.0K	$279.0K	$316.0K
YoY Change	-43.0%	-41.88%	-36.93%
Total Long-Term Assets	$38.14M	$40.57M	$40.27M
YoY Change	-5.1%	1109.84%	1013.77%
TOTAL ASSETS
Total Short-Term Assets	$71.31M	$78.76M	$69.12M
Total Long-Term Assets	$38.14M	$40.57M	$40.27M
Total Assets	$109.5M	$119.3M	$109.4M
YoY Change	27.97%	113.6%	70.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.565M	$2.334M	$2.865M
YoY Change	-54.86%	-9.22%	3.09%
Accrued Expenses	$8.127M	$8.971M	$9.495M
YoY Change	-6.59%	-4.56%	7.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.692M	$11.31M	$12.36M
YoY Change	-20.22%	-5.8%	6.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.601M	$2.870M	$631.0K
YoY Change	116.75%	91.33%	-64.94%
Total Long-Term Liabilities	$2.601M	$2.870M	$631.0K
YoY Change	116.75%	91.33%	-64.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.692M	$11.31M	$12.36M
Total Long-Term Liabilities	$2.601M	$2.870M	$631.0K
Total Liabilities	$12.29M	$14.18M	$12.99M
YoY Change	-8.13%	4.91%	-2.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$266.4M	-$257.1M	-$246.5M
YoY Change	19.38%	2.63%	2.41%
Common Stock	$361.7M	$360.9M	$341.5M
YoY Change	22.48%	23.25%	17.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$97.16M	$105.1M	$96.40M
YoY Change
Total Liabilities & Shareholders Equity	$109.5M	$119.3M	$109.4M
YoY Change	27.97%	113.6%	70.46%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021 Q2
OPERATING ACTIVITIES
Net Income	-$9.236M	-$10.67M	-$11.75M
YoY Change	-133.77%	8.95%	10.75%
Depreciation, Depletion And Amortization	$93.00K	$108.0K	$119.0K
YoY Change	-33.57%	-28.0%	-25.63%
Cash From Operating Activities	-$6.856M	-$8.425M	-$12.64M
YoY Change	-16.49%	8.99%	33.23%
INVESTING ACTIVITIES
Capital Expenditures	-$5.000K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$1.994M	$3.471M	$15.24M
YoY Change	-524.26%	-65.32%	128.46%
Cash From Investing Activities	-$1.999M	$3.471M	$15.24M
YoY Change	-534.57%	-65.08%	128.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	18.00K	18.33M	11.22M
YoY Change	-98.52%	26091.43%	55980.0%
NET CHANGE
Cash From Operating Activities	-6.856M	-8.425M	-12.64M
Cash From Investing Activities	-1.999M	3.471M	15.24M
Cash From Financing Activities	18.00K	18.33M	11.22M
Net Change In Cash	-8.837M	13.38M	13.81M
YoY Change	35.33%	486.84%	-593.21%
FREE CASH FLOW
Cash From Operating Activities	-$6.856M	-$8.425M	-$12.64M
Capital Expenditures	-$5.000K	$0.00
Free Cash Flow	-$6.851M	-$8.425M
YoY Change	-16.55%	10.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41854110
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29478878
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29349810
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41854110
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29478878
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29349810
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28372634
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46553511
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.92
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001626971
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	City Area Code CityAreaCode	650
CY2021	dei	Local Phone Number LocalPhoneNumber	900-4520
CY2021	dei	Security12b Title Security12bTitle	Common Stock
CY2021	dei	Trading Symbol TradingSymbol	CRVS
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021Q3	crvs	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	2400000
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	65000000.0
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	46553511
CY2021	dei	Auditor Firm AuditorFirmId	238
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity Registrant Name EntityRegistrantName	Corvus Pharmaceuticals, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity File Number EntityFileNumber	001-37719
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4670809
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	863 Mitten Road, Suite 102
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Burlingame
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94010
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	San Jose, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63458000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16455000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5993000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	27804000
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	507000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1354000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1077000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	71312000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	45336000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	451000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	906000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3190000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1648000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	34266000
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	37225000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	236000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	414000
CY2021Q4	us-gaap	Assets Assets	109455000
CY2020Q4	us-gaap	Assets Assets	85529000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1565000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3467000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1046000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1078000
CY2021Q4	crvs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7081000
CY2020Q4	crvs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7604000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9692000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12149000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2601000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1232000
CY2021Q4	us-gaap	Liabilities Liabilities	12293000
CY2020Q4	us-gaap	Liabilities Liabilities	13381000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46553511
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28372634
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	5000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	361669000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	295281000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1869000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-266381000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-223140000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	97162000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	72148000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	109455000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	85529000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29115000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31830000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37975000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9515000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11930000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10879000
CY2021	us-gaap	Operating Expenses OperatingExpenses	38630000
CY2020	us-gaap	Operating Expenses OperatingExpenses	43760000
CY2019	us-gaap	Operating Expenses OperatingExpenses	48854000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-38630000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-43760000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-48854000
CY2021	crvs	Interest Income And Other Expense Net InterestIncomeAndOtherExpenseNet	-15000
CY2020	crvs	Interest Income And Other Expense Net InterestIncomeAndOtherExpenseNet	540000
CY2019	crvs	Interest Income And Other Expense Net InterestIncomeAndOtherExpenseNet	2182000
CY2020	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	37459000
CY2021	crvs	Sublease Income Related Party SubleaseIncomeRelatedParty	235000
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-4831000
CY2020	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-234000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-43241000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5995000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-46672000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41854110
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29478878
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29349810
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-25000
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	63000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1872000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41376000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6020000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46609000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	110336000
CY2019	crvs	Common Stock Warrant Issued In Exchange For Retirement Of Common Stock Value CommonStockWarrantIssuedInExchangeForRetirementOfCommonStockValue	5030000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	24000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	12000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7348000
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	63000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-46672000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	71111000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	88000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5747000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-25000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5995000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	72148000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1215000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4232000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-7000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1872000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-43241000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	97162000
CY2021	us-gaap	Profit Loss ProfitLoss	-43241000
CY2020	us-gaap	Profit Loss ProfitLoss	-5995000
CY2019	us-gaap	Profit Loss ProfitLoss	-46672000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	460000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	632000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	743000
CY2021	crvs	Amortization Accretion Related To Marketable Securities AmortizationAccretionRelatedToMarketableSecurities	239000
CY2020	crvs	Amortization Accretion Related To Marketable Securities AmortizationAccretionRelatedToMarketableSecurities	154000
CY2019	crvs	Amortization Accretion Related To Marketable Securities AmortizationAccretionRelatedToMarketableSecurities	-644000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	4232000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5747000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	7348000
CY2020	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	37459000
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-4831000
CY2020	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-234000
CY2021	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	507000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	277000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-285000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	370000
CY2021	crvs	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-1542000
CY2020	crvs	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	679000
CY2019	crvs	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	599000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-178000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-99000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	50000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1902000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1019000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	450000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-523000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	705000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2042000
CY2021	crvs	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1337000
CY2020	crvs	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	878000
CY2019	crvs	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	767000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36715000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34778000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37321000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	9357000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	42540000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	138586000
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1009000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	30922000
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	86376000
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	141866000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	76000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21560000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	44769000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3255000
CY2021	crvs	Proceeds From Issuance Of Common Stock Related Party ProceedsFromIssuanceOfCommonStockRelatedParty	4850000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	31989000
CY2021	crvs	Proceeds From Issuance Of Common Stocks For Market Offers ProceedsFromIssuanceOfCommonStocksForMarketOffers	28954000
CY2020	crvs	Proceeds From Issuance Of Common Stocks For Market Offers ProceedsFromIssuanceOfCommonStocksForMarketOffers	1222000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1215000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	88000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	24000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	62158000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1310000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	47003000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11301000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34042000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16455000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5154000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39196000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63458000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16455000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5154000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Organization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Corvus Pharmaceuticals, Inc. (“Corvus” or the “Company”) was incorporated in Delaware on January 27, 2014 and commenced operations in November 2014. Corvus is a clinical-stage biopharmaceutical company. The Company’s operations are located in Burlingame, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Corvus Biopharmaceuticals, Ltd. and Corvus Hong Kong Limited. All significant intercompany accounts and transactions have been eliminated from the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Initial Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 22, 2016, the Company’s registration statement on Form S-1 (File No. 333-208850) relating to its initial public offering (“IPO”) of its common stock was declared effective by the Securities and Exchange Commission (“SEC”) and the shares of its common stock began trading on the Nasdaq Global Market on March 23, 2016. The public offering price of the shares sold in the IPO was $15.00 per share. The IPO closed on March 29, 2016, pursuant to which the Company sold 4,700,000 shares of its common stock. On April 26, 2016, the Company sold an additional 502,618 shares of its common stock to the underwriters upon partial exercise of their over-allotment option, at the initial offering price of $15.00 per share. The Company received aggregate net proceeds of approximately $70.6 million, after underwriting discounts, commissions and offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of convertible preferred stock were converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Follow-on Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In March 2018, the Company completed a follow-on public offering in which the Company sold 8,117,647 shares of common stock at a price of $8.50 per share, which included 1,058,823 shares issued pursuant to the underwriters’ exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $64.9 million, net of underwriting discounts and commissions and offering expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In February 2021, the Company completed a follow-on public offering in which the Company sold 9,783,660 shares of common stock at a price of $3.50 per share, which included 1,212,231 shares issued pursuant to the underwriters’ exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $32.0 million, net of underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Since commencing operations in 2014, the majority of the Company’s efforts have been focused on the research and development of mupadolimab (formerly CPI-006), CPI-818 and ciforadenant. The Company believes that it will continue to expend substantial resources for the foreseeable future as it continues clinical development of, seek regulatory approval for and, if approved, prepare for the commercialization of mupadolimab, CPI-818 and ciforadenant, as well as product candidates under the Company’s other development programs. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, obtaining regulatory </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">approvals, manufacturing and supply, sales and marketing and general operations. In addition, other unanticipated costs may arise. Because the outcome of any clinical trial and/or regulatory approval process is highly uncertain, the Company may not be able to accurately estimate the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of mupadolimab, CPI-818, and ciforadenant or any other product candidates. The Company does not expect its existing capital resources to be sufficient to enable it to fund the completion of its clinical trials and remaining development program of mupadolimab, CPI-818 and ciforadenant through commercialization. In addition, its operating plan may change as a result of many factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>The Company has incurred significant losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $266.4 million as of December 31, 2021. The Company has historically financed its operations primarily through the sale of redeemable convertible preferred stock and common stock. While the Company has been able to raise multiple rounds of financing, there can be no assurance that in the event the Company requires additional financing, such financing will be available on terms which are favorable or at all. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending would have a material adverse effect on the Company’s ability to achieve its intended business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>As of December 31, 2021, the Company had cash, cash equivalents and short-term marketable securities of $69.5 million. Management believes that the Company’s current cash, cash equivalents and short-term marketable securities will be sufficient to fund its planned operations for at least 12 months from the date of the issuance of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>The current COVID-19 (coronavirus) pandemic, which is impacting worldwide economic activity, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The extent to which COVID-19 impacts the Company’s business, including its clinical trials and financial condition, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the impact of variants of the COVID-19 virus, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. As COVID-19 continues to spread around the globe, including the spread of more contagious and virulent variants, we will likely experience disruptions, including delays or difficulties in enrolling patients in our clinical trials, delays or difficulties in clinical site initiation, interruption of key clinical trial activities, delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials and delays in necessary interactions with local regulatory authorities. COVID-19 may also impact the Company’s ability to raise additional capital on a timely basis or at all, which could negatively impact short-term and long-term liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Exchange Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On November 8, 2019, the Company entered into an exchange agreement (the “Exchange Agreement”) with an investor and its affiliates (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 1,458,000 shares of the Company’s common stock, par value $0.0001 per share, owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 1,458,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.0001 per share. The Exchange Warrants were exercisable at any time prior to expiration except that the Exchange Warrants could not be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would have beneficially owned more than 9.99% of the Company’s common stock, subject to certain exceptions. In accordance with Accounting Standards Codification Topic 505, Equity, and Accounting Research Bulletin 43, the Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and elected to record the excess over par value as a debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants were classified as equity in accordance with Accounting Standards Codification Topic 480, Distinguishing Liabilities from Equity, and Accounting Standards Codification Topic 815, Derivatives and Hedging, and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants was substantially </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, the Exchange Warrants were fully exercised, resulting in the issuance of 1,457,947 shares of common stock on a net exercise basis.</p>
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-266400000
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	69500000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-266400000
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	69500000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</p>
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1400000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Substantially all of the Company’s cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company’s marketable securities consist of investments in U.S. Treasury securities and U.S. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">government agency securities, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</p>
CY2021	crvs	Number Of Financial Institutions NumberOfFinancialInstitutions	2
CY2019	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	14725
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41854110
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	27804000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29478878
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29349810
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-43241000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5995000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-46672000
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	41854110
CY2020	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29478878
CY2019	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29364535
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021	crvs	Maximum Remaining Maturity Of Marketable Securities MaximumRemainingMaturityOfMarketableSecurities	P11M
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5993000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	27800000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	5996000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2020Q4	crvs	Prepaid Facility Expenses PrepaidFacilityExpenses	160000
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	32000
CY2020Q4	us-gaap	Interest Receivable InterestReceivable	86000
CY2021Q4	crvs	Prepaid Research And Development Manufacturing Expenses PrepaidResearchAndDevelopmentManufacturingExpenses	740000
CY2020Q4	crvs	Prepaid Research And Development Manufacturing Expenses PrepaidResearchAndDevelopmentManufacturingExpenses	181000
CY2021Q4	crvs	Prepaid Facility Expenses PrepaidFacilityExpenses	174000
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	244000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	128000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	406000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1354000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	280000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1077000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4703000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4698000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4252000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3792000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	451000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	906000
CY2021Q4	crvs	Accrual For Preclinical And Clinical Trial Current AccrualForPreclinicalAndClinicalTrialCurrent	4010000
CY2020Q4	crvs	Accrual For Preclinical And Clinical Trial Current AccrualForPreclinicalAndClinicalTrialCurrent	4681000
CY2021Q4	crvs	Accrued Manufacturing Expense Current AccruedManufacturingExpenseCurrent	839000
CY2020Q4	crvs	Accrued Manufacturing Expense Current AccruedManufacturingExpenseCurrent	321000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1846000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2225000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	265000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	197000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	121000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	180000
CY2021Q4	crvs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7081000
CY2020Q4	crvs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7604000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	crvs	Common Stock Voting Rights Number Of Votes Per Share CommonStockVotingRightsNumberOfVotesPerShare	1
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	0
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1458000
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1458000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2806953
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1692753
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1704183
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6354308
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6664173
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5643410
CY2021Q4	crvs	Number Of Shares Reserved For Employee Stock Purchase Plan NumberOfSharesReservedForEmployeeStockPurchasePlan	400000
CY2020Q4	crvs	Number Of Shares Reserved For Employee Stock Purchase Plan NumberOfSharesReservedForEmployeeStockPurchasePlan	400000
CY2019Q4	crvs	Number Of Shares Reserved For Employee Stock Purchase Plan NumberOfSharesReservedForEmployeeStockPurchasePlan	400000
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9561261
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6000000.0
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10214926
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9205593
CY2020	crvs	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Vested Options Weighted Average Remaining Contractual Term ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm	P6Y2M19D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	10.23
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.93
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.66
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.53
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6354308
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y7M24D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	6.80
CY2021Q4	crvs	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Vested Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions	3783385
CY2021	crvs	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Vested Options Weighted Average Remaining Contractual Term ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm	P5Y10D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	9.09
CY2020Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6664173
CY2020	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y8M19D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	7.26
CY2020Q4	crvs	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Vested Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions	3209532
CY2021Q4	crvs	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber	3783385
CY2021Q4	crvs	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice	9.09
CY2021	crvs	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding And Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm	P5Y10D
CY2021Q4	crvs	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding And Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue	105000
CY2021Q4	crvs	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber	2570923
CY2021Q4	crvs	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice	3.43
CY2021	crvs	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding And Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm	P9Y10D
CY2021	crvs	Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Fair Value Of Common Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock	2.41
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000000.0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4500000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	7800000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4942000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4317000
CY2021Q4	crvs	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1021000
CY2020Q4	crvs	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	646000
CY2019Q4	crvs	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	892000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	12000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	47000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	40000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4232000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5747000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7348000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-43241000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-5995000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-46672000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43241000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5995000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46672000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	68021000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	56143000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	54874000
CY2021Q4	crvs	Deferred Tax Liabilities Lease Right Of Use Asset DeferredTaxLiabilitiesLeaseRightOfUseAsset	893000
CY2020Q4	crvs	Deferred Tax Liabilities Lease Right Of Use Asset DeferredTaxLiabilitiesLeaseRightOfUseAsset	461000
CY2019Q4	crvs	Deferred Tax Liabilities Lease Right Of Use Asset DeferredTaxLiabilitiesLeaseRightOfUseAsset	651000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67128000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	55682000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54223000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.09
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.14
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	63000
CY2019Q4	crvs	Deferred Tax Assets Capitalized Tax Assets DeferredTaxAssetsCapitalizedTaxAssets	-3000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.26
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.24
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.28
CY2021	crvs	Effective Income Tax Rate Reconciliation Tax Credit Research And Development Percent EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent	0.03
CY2020	crvs	Effective Income Tax Rate Reconciliation Tax Credit Research And Development Percent EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent	0.19
CY2019	crvs	Effective Income Tax Rate Reconciliation Tax Credit Research And Development Percent EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent	0.04
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	137000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	207000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	152000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5006000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.10
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.01
CY2020	crvs	Effective Income Tax Rate Reconciliation Employees Compensation Limitation EffectiveIncomeTaxRateReconciliationEmployeesCompensationLimitation	-0.06
CY2021	crvs	Effective Income Tax Rate Reconciliation Reserve For Uncertain Tax Positions Percent EffectiveIncomeTaxRateReconciliationReserveForUncertainTaxPositionsPercent	-0.01
CY2020	crvs	Effective Income Tax Rate Reconciliation Reserve For Uncertain Tax Positions Percent EffectiveIncomeTaxRateReconciliationReserveForUncertainTaxPositionsPercent	-1.61
CY2019	crvs	Effective Income Tax Rate Reconciliation Reserve For Uncertain Tax Positions Percent EffectiveIncomeTaxRateReconciliationReserveForUncertainTaxPositionsPercent	-0.01
CY2021	crvs	Effective Income Tax Rate Reconciliation Deconsolidation Gain EffectiveIncomeTaxRateReconciliationDeconsolidationGain	-0.03
CY2020	crvs	Effective Income Tax Rate Reconciliation Deconsolidation Gain EffectiveIncomeTaxRateReconciliationDeconsolidationGain	1.74
CY2020	crvs	Effective Income Tax Rate Reconciliation Gain On Transfer Of Intellectual Property Percent EffectiveIncomeTaxRateReconciliationGainOnTransferOfIntellectualPropertyPercent	-0.20
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.07
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52539000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42344000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42486000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	9181000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7894000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6990000
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	125000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1645000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1506000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	1449000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11400000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1500000
CY2020Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	35000000.0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12500000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12157000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1885000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1804000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	365000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	347000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	10272000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	446000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12504000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12157000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1885000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2018Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2019Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2020	crvs	Income Tax Examination For Federal Or State IncomeTaxExaminationForFederalOrState	0
CY2015Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	8138
CY2015Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P1Y
CY2021Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	27280
	crvs	Landlord Provided Free Rent And Lease Incentives LandlordProvidedFreeRentAndLeaseIncentives	1900000
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2021Q3	crvs	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	2400000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3200000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1600000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1046000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	957000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	960000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	396000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	351000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	324000
CY2021	us-gaap	Lease Cost LeaseCost	1442000
CY2020	us-gaap	Lease Cost LeaseCost	1308000
CY2019	us-gaap	Lease Cost LeaseCost	1284000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1299000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2559000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	249000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2310000
CY2021Q3	crvs	Area Of Property Subleased AreaOfPropertySubleased	7585
CY2021	crvs	Sublease Income Related Party SubleaseIncomeRelatedParty	200000
CY2015Q3	us-gaap	Security Deposit SecurityDeposit	100000
CY2021Q3	crvs	Area Of Property Subleased AreaOfPropertySubleased	7585
CY2021	crvs	Sublease Income Related Party SubleaseIncomeRelatedParty	200000
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	6810000
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	9047000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	11290000
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	11483000
CY2021Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9236000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10673000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1300000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1391000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1434000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4125000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	478000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3647000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1260000
CY2021Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	9300000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-11752000
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-11580000
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	9879000
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	9845000
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	10767000
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	13269000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	27347000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-9796000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-10611000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12935000
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.92
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44

Files In Submission

Name	View Source	Status
0001558370-22-003281-index-headers.html	Edgar Link	pending
0001558370-22-003281-index.html	Edgar Link	pending
0001558370-22-003281.txt	Edgar Link	pending
0001558370-22-003281-xbrl.zip	Edgar Link	pending
crvs-20211231.xsd	Edgar Link	pending
crvs-20211231x10k.htm	Edgar Link	pending
crvs-20211231x10k007.jpg	Edgar Link	pending
crvs-20211231x10k_htm.xml	Edgar Link	completed
crvs-20211231xex10d18.htm	Edgar Link	pending
crvs-20211231xex21d1.htm	Edgar Link	pending
crvs-20211231xex23d1.htm	Edgar Link	pending
crvs-20211231xex31d1.htm	Edgar Link	pending
crvs-20211231xex31d2.htm	Edgar Link	pending
crvs-20211231xex32d1.htm	Edgar Link	pending
crvs-20211231_cal.xml	Edgar Link	unprocessable
crvs-20211231_def.xml	Edgar Link	unprocessable
crvs-20211231_lab.xml	Edgar Link	unprocessable
crvs-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRVS
Corvus Pharmaceuticals, Inc. Stock $crvs

2021 Q4 Form 10-K Financial Statement

#000155837022003281 Filed on March 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRVS Corvus Pharmaceuticals, Inc. Stock $crvs

2021 Q4 Form 10-K Financial Statement

#000155837022003281 Filed on March 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRVS
Corvus Pharmaceuticals, Inc. Stock $crvs